[Basis for a specific-active immunotherapy in malignant melanoma].

Journal Article (English Abstract;Journal Article)

Since Morton demonstrated in 1968 that malignant melanoma is antigenic, many immunologists have taken an interest in this disease. A basis for specific active immunotherapy has been worked out at Duke University Medical Center, Durham, N.C. (USA). A female chimpanzee was hyperimmunized with melanoma cells grown in tissue culture. After appropriate absorptions the xeno-antiserum was tested by indirect immunofluorescence. Apart from unspecific activities in the serum detectable against normal human fetal and adult fibroblasts as well as other non-melanotic human tumors, following further absorptions with these cells a melanoma-specific antigen could be demonstrated on the surfaces of melanoma cells. The melanoma-specific tumor-associated antigens were further evaluated by direct and indirect immunoautoradiography. These studies suggest that there are indeed cross-reacting specific tumor-associated antigens on the cell surface of melanoma cells. At DUMC melanoma patients have therefore been hyperimmunized with melanoma cells + BCG. Clinical experience is discussed.

Full Text

Duke Authors

Cited Authors

  • Mutzner, PA; Stuhlmiller, GM; Seigler, HF; Stumpf, WE; Sar, M

Published Date

  • September 5, 1981

Published In

Volume / Issue

  • 111 / 36

Start / End Page

  • 1322 - 1325

PubMed ID

  • 7302537

International Standard Serial Number (ISSN)

  • 0036-7672


  • ger

Conference Location

  • Switzerland